FDA Clears Path for Generic Rectiv Ointment
Published Date: 6/26/2026
Notice
Summary
The FDA has decided that RECTIV (nitroglycerin) ointment, 0.4%, wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can keep getting approved as long as they follow the rules, so patients and pharmacies won’t face shortages or price spikes. If you’re a drug maker or user, this is good news for steady access and affordable options.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 1 costs, 1 mixed.
Generic Approvals May Continue
The FDA determined on publication June 26, 2026 that RECTIV (nitroglycerin) ointment, 0.4% was not withdrawn for reasons of safety or effectiveness. Because of that determination, FDA will not begin procedures to withdraw approval of approved abbreviated new drug applications (ANDAs) that refer to RECTIV, and additional ANDAs may be approved if they meet legal and regulatory requirements.
Product Remains on Discontinued List
FDA will continue to list RECTIV (nitroglycerin) ointment, 0.4% in the Orange Book's "Discontinued Drug Product List," indicating the product is discontinued from marketing for reasons other than safety or effectiveness. AbbVie notified FDA of the discontinuation on March 27, 2026; the NDA was initially approved on June 21, 2011.
Labeling Updates May Be Requested
If FDA determines that labeling for RECTIV should be revised to meet current standards, the Agency will advise ANDA applicants to submit updated labeling. Aurobindo Pharma USA submitted a citizen petition on April 23, 2026, prompting this determination.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12899 — Medical Devices; General Hospital and Personal Use Devices; Classification of the Foam or Gel Chemical Sterilant/High Level Disinfectant
The FDA is officially putting foam or gel chemical sterilants and high-level disinfectants into Class II, meaning they’ll have special safety rules but fewer red tape hurdles. This change helps companies bring safer, innovative cleaning products to hospitals and homes faster, starting June 26, 2026. If you make or use these devices, expect smoother approvals and better access without extra costs or delays.
2026-12959 — Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that the 5 mg prednisolone tablet wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions of this medicine, as long as they follow the rules. Patients and pharmacies can expect continued access to affordable generics without any interruptions or extra costs.
2026-12937 — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period
The FDA is giving folks more time to share their thoughts on whether certain medicines like semaglutide, tirzepatide, and liraglutide should be allowed for special compounding by outsourcing drug makers. This extension means anyone interested has until July 30, 2026, to weigh in. It affects drug makers, healthcare pros, and patients waiting for these meds, with no immediate cost changes but plenty of chances to influence future drug availability.
2026-12906 — Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability
The FDA has officially ended emergency use for three COVID-19 test kits from BD, InBios, and Roche as of early 2026. This means these specific tests are no longer authorized for quick COVID-19 detection or diagnosis. If you or your organization used these tests, it’s time to switch to other approved options—no extra costs or penalties, just a smooth transition.
2026-12933 — Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
The FDA is giving itself 90 more days—until September 24, 2026—to finish reviewing important feedback about certain estrogen-androgen combo drugs like Syntest tablets. This means the final decisions about these drugs’ approval are on hold a bit longer, affecting drug makers and patients waiting for updates. No extra costs are mentioned, just more time to get it right!
2026-12900 — Medical Devices; Clinical Chemistry and Toxicology Devices; Classification of the Prognostic Test for Development or Progression of Preeclampsia
The FDA is officially putting the test that predicts preeclampsia risk into a safer, easier-to-get category called Class II. This change helps make sure the test works well and is safe, while also making it simpler for patients to access this important health tool. The new rules took effect on June 26, 2026, but the classification has been in place since May 18, 2023, helping companies save time and money on approvals.
Previous / Next Documents
Previous: 2026-12952 — Production Activity Not Authorized; Foreign-Trade Zone (FTZ) 75; Catalina Components, Inc.; (Vehicle Parts); Chandler, Arizona; Correction
Catalina Components, Inc. in Chandler, Arizona, didn’t get approval to start production in Foreign-Trade Zone 75, and this notice fixes a small mistake in the official paperwork. The correction changes the docket number to the right one, making sure the record is clear and accurate. No new money or timing changes—just a tidy update to keep things straight!
Next: 2026-12954 — Harbert Mezzanine Partners II SBIC, L.P.; Surrender of License of Small Business Investment Company
Harbert Mezzanine Partners II SBIC, L.P. has officially given up its license to operate as a Small Business Investment Company. This means they won’t be making new investments under this program anymore. The change is effective immediately, so small businesses looking for funding from them will need to look elsewhere.